NASH market and competitionThere is a reason analysts are not assigning much value for Thera's NASH program. The market is huge but not for Egrifta. Oral meds will dominate the NASH treatment market unless there is a significant advantage with a particular injectable drug. Similar results to using Egrifta can be achieved through diet, exercise and weight loss.
"
The first line of treatment for NAFLD and NASH is weight loss, done through a combination of calorie reduction, exercise, and healthy eating. Weight loss can reduce fat and inflammation in the liver. "
Spending money and resources on a NASH program is not the most effective use of company resources right now. License it out if they want to pursue this market.
https://www.pharmaceuticalonline.com/doc/analysis-of-the-non-alcoholic-steatohepatitis-nash-drug-pipeline-market-sizing-up-the-first-wave-0001 The opportunity for TH in oncology is multiple times larger and 4-5 years sooner than any NASH potential. That is where all resources should be directed.